CHOP plus alemtuzumab can induce metabolic response by FDG-PET but has minimal long-term benefits: A case report and literature review

Sheetal M. Kircher, Sandeep Gurbuxani, Sonali M. Smith

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'CHOP plus alemtuzumab can induce metabolic response by FDG-PET but has minimal long-term benefits: A case report and literature review'. Together they form a unique fingerprint.

Medicine & Life Sciences